Cargando…

Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis

BACKGROUND: We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC). METHODS: Eligible prospective and controlled randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jianxin, Wang, Junhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571363/
https://www.ncbi.nlm.nih.gov/pubmed/31169742
http://dx.doi.org/10.1097/MD.0000000000015999
_version_ 1783427398964871168
author Chen, Jianxin
Wang, Junhui
author_facet Chen, Jianxin
Wang, Junhui
author_sort Chen, Jianxin
collection PubMed
description BACKGROUND: We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC). METHODS: Eligible prospective and controlled randomized clinical trials (RCT) were included, of which data were extracted by inclusion criteria and exclusion ones. Odds ratio (OR) and Hazard ratio (HR) of outcomes including objective response rate (ORR), disease control rate (DCR), progressive-free survival (PFS), overall survival (OS), and adverse events (AEs) were explored for the final analysis between the 2 groups. RESULTS: A total of 23 eligible prospective, controlled RCTs including 2269 patients were enrolled for the pooled analysis. With the meta-analysis of available data, the results of the present research showed that there was no statistical difference on short-term efficacy including ORR (HR = 0.85, 95% CI: 0.71–1.01; P = .07) or DCR (HR = 0.88, 95% CI: 0.69–1.11; P = .27), as well as long-term efficacy including PFS (HR = 1.00, 95% CI: 0.90–1.11; P = .98) or OS (HR = 0.95, 95% CI: 0.82–1.10; P = .50). In addition, the incidences of AEs including leucopenia, neutropenia, and vomiting were statistically lower in S-1-based regimens comparing to intravenous fluorouracil-based ones, regardless of all grade or high grade (all P <.05). However, there were no significant differences detected among other AEs including anemia, thrombocytopenia, increased alanine aminotransferase concentration, stomatitis, anorexia, diarrhea, hand–foot syndrome (HFS), or sensory neuropathy among the 2 groups (all P >.05). CONCLUSIONS: The present meta-analysis revealed that S-1-based regimens might be associated with comparable efficacy, as well as lower risk of leucopenia, neutropenia, and vomiting at all/high grade comparing to intravenous fluorouracil-based ones in Asian patients with mCRC.
format Online
Article
Text
id pubmed-6571363
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-65713632019-07-22 Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis Chen, Jianxin Wang, Junhui Medicine (Baltimore) Research Article BACKGROUND: We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC). METHODS: Eligible prospective and controlled randomized clinical trials (RCT) were included, of which data were extracted by inclusion criteria and exclusion ones. Odds ratio (OR) and Hazard ratio (HR) of outcomes including objective response rate (ORR), disease control rate (DCR), progressive-free survival (PFS), overall survival (OS), and adverse events (AEs) were explored for the final analysis between the 2 groups. RESULTS: A total of 23 eligible prospective, controlled RCTs including 2269 patients were enrolled for the pooled analysis. With the meta-analysis of available data, the results of the present research showed that there was no statistical difference on short-term efficacy including ORR (HR = 0.85, 95% CI: 0.71–1.01; P = .07) or DCR (HR = 0.88, 95% CI: 0.69–1.11; P = .27), as well as long-term efficacy including PFS (HR = 1.00, 95% CI: 0.90–1.11; P = .98) or OS (HR = 0.95, 95% CI: 0.82–1.10; P = .50). In addition, the incidences of AEs including leucopenia, neutropenia, and vomiting were statistically lower in S-1-based regimens comparing to intravenous fluorouracil-based ones, regardless of all grade or high grade (all P <.05). However, there were no significant differences detected among other AEs including anemia, thrombocytopenia, increased alanine aminotransferase concentration, stomatitis, anorexia, diarrhea, hand–foot syndrome (HFS), or sensory neuropathy among the 2 groups (all P >.05). CONCLUSIONS: The present meta-analysis revealed that S-1-based regimens might be associated with comparable efficacy, as well as lower risk of leucopenia, neutropenia, and vomiting at all/high grade comparing to intravenous fluorouracil-based ones in Asian patients with mCRC. Wolters Kluwer Health 2019-06-07 /pmc/articles/PMC6571363/ /pubmed/31169742 http://dx.doi.org/10.1097/MD.0000000000015999 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Chen, Jianxin
Wang, Junhui
Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis
title Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis
title_full Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis
title_fullStr Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis
title_full_unstemmed Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis
title_short Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis
title_sort efficacy and safety assessment of s-1-based regimens comparing to intravenous fluorouracil-based ones in asian patients with metastatic colorectal carcinoma: a system review and meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571363/
https://www.ncbi.nlm.nih.gov/pubmed/31169742
http://dx.doi.org/10.1097/MD.0000000000015999
work_keys_str_mv AT chenjianxin efficacyandsafetyassessmentofs1basedregimenscomparingtointravenousfluorouracilbasedonesinasianpatientswithmetastaticcolorectalcarcinomaasystemreviewandmetaanalysis
AT wangjunhui efficacyandsafetyassessmentofs1basedregimenscomparingtointravenousfluorouracilbasedonesinasianpatientswithmetastaticcolorectalcarcinomaasystemreviewandmetaanalysis